Cefuroxime axetil in acute purulent exacerbations of chronic bronchitis.
51 hospitalised patients with acute purulent exacerbations of chronic bronchitis were treated for ten days with two daily 1 g doses of the orally absorbed pro-drug cefuroxime axetil. However, some patients were still infected with Haemophilus influenzae or Branhamella catarrhalis at follow-up, and sputum purulence remained. Clinical results were "excellent" or "good" in 60% of the evaluable patients one week after the end of the treatment. Mean peak serum concentrations averaged 12.8 mg/l with mean peak sputum concentrations of 1.8 mg/l. The MIC90 value for H. influenzae was 4 mg/l. Three patients discontinued cefuroxime because of unwanted gastrointestinal drug effects, and three because of insufficient improvement. These results do not suggest that this compound is indicated for such patients.
Davies
B I
BI
Department of Medical Microbiology, De Wever Ziekenhuis, Heerlen.
Maesen
F P
FP
Teengs
J P
JP
D000208:Acute Disease; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy*; D002444:Cefuroxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002511:Cephalosporins; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004358:Drug Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011355:Prodrugs / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013183:Sputum / Q000378:metabolism
D002511:Cephalosporins; D011355:Prodrugs; D002444:Cefuroxime; C040738:cefuroxime axetil